Ambrx Appoints Jared Kelly as General Counsel

SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced the appointment of Jared Kelly as Senior Vice President, General Counsel and Corporate Secretary. After practicing for more than ten years at large corporate law firms, Mr. Kelly brings his extensive experience advising public companies on corporate governance, financing transactions and mergers and acquisitions to Ambrx. He will be responsible for developing and overseeing the legal strategy of the Company and for providing legal guidance to the Company’s board of directors, executive management team and other business units.

Mr. Kelly is an experienced public company lawyer who began his career with Kirkland & Ellis LLP where he represented various public companies in securities offerings, IPOs and merger transactions. He most recently served as a partner at Lowenstein Sandler LLP where his practice focused on representing biotechnology companies in financing transactions, mergers and acquisitions and other complex transactions. Mr. Kelly received his J.D. and an LL.M. in Securities and Financial Regulation from Georgetown University Law Center, where he was the recipient of multiple honors and fellowships, including the Lane Evans Fellowship and Decrane Scholarship.

“Ambrx welcomes Jared Kelly, whose wealth of experience as a member of world-leading law firms representing public companies in corporate and securities law, particularly in the biotech sector, makes him a tremendous asset to our team,” said Daniel J. O’Connor, Chief Executive Officer of Ambrx. “His notable track record of advising numerous companies on significant M&A and financing transactions and serving as outside general counsel for a variety of clients is indicative of his exceptional legal and business acumen. We are excited to welcome him to Ambrx and believe he will play an integral role in advancing our strategic objectives.”

“I am thrilled to join Ambrx—a company with a strong reputation for scientific excellence on the cutting-edge of biotechnology,” said Mr. Kelly. “To have the opportunity to use my legal experience to help develop innovative therapies that address unmet medical needs is extremely humbling and rewarding. I am excited to help the Company continue its focus on achieving its strategic goals and driving value for shareholders.”